Performing Randomized Clinical Trials for DTx products can be complex due to high costs, timings and constantly evolving softwares and devices. Are RCTs necessary for DTx clinical validation in a DTx-Pharma partnership? What level of data validation is needed for these partnerships to be successful? Can we use RWE to display benefits faster and speed up the go-to-market process? How can we put some rigor around the real-world data generated so that it can be used for a decision maker such as pharma and investors? What are the main challenges when building evidence outcomes from aggregating RWE derived from multiple sources? Join us in this meeting to deep dive into the power of RWE in DTx-Pharma partnerships.